Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
Urinary hydroxyproline was elevated significantly in patients with untreated stage D prostatic carcinoma when compared to values in patients with benign prostatic hypertrophy and prostatic carcinoma without bony metastasis. Our results indicate that hydroxyproline may be a valuable marker in early staging, followup and evaluating treatment in prostatic cancer.
D001859:Bone Neoplasms / Q000556:secondary*; D002277:Carcinoma / Q000556:secondary*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000652:urine*
D006909:Hydroxyproline